NCT01369862View on ClinicalTrials.gov

Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Influenza, Human
Interventions
BIOLOGICAL

GHB16L2

A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants

BIOLOGICAL

Placebo

SPGNH buffer

Trial Locations (1)

1090

Medical University Vienna, Department of Clinical Pharmacology, Vienna

Sponsors
All Listed Sponsors
lead

AVIR Green Hills Biotechnology AG

INDUSTRY

NCT01369862 - Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter